Incidence, outcome and prediction of early clinical events following percutaneous transluminal coronary angioplasty: A comparison between treatment with reviparin and unfractionated heparin/placebo (results of a substudy of the REDUCE Trial)

European Heart Journal

Volumn 19, Issue 8, 1998, Pages 1232-1238

  Preisack, Melitta B ^a,b   Bonan, R ^a   Meisner, C ^a   Eschenfelder, V ^a   Karsch, K R ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Department of Cardiology ^*  (Germany)

Author keywords

Clinical trials; Coronary angioplasty; Early acute events

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; REVIPARIN;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY OBSTRUCTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGINA PECTORIS; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; FEMALE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME;

EID: 0032146981     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1998.1054     Document Type: Article

References (18)

1. [1] Ellis SG, Roubin GS, King III SB et al. Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. Circulation 1988; 77: 372-9.
2. [2] Detre KM, Holmes DR, Holubkov R et al and co-investigators NHLBI PTCA Registry. Incidence and consequences of periprocedural occlusion. The 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1990; 82: 739-50.
3. [3] de Feyter PJ, van den Brand M, Laarman GJ, van Domburg R, Serruys PW Suryapranata H. Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty: frequency, prediction, clinical course, management and follow-up. Circulation 1991; 83: 927-36.
4. [4] Boneu B. An international multicenter study: reviparin in the prevention of venous thromboembolism in patients undergoing general surgery. Blood Coagulation and Fibrinolysis 1993; 4: S21-2.
5. [5] Planes A, Chastang C, Vochelle N, Desmichels D, Alach M, Fiessinger JN. Comparison of antithrombotic efficacy and hemorrhagic side-effects of reviparin-sodium versus enoxiparin in patients undergoing total hip replacement. Blood Coagulation and Fibrinolysis 1993; 4: S33-5.
6. [6] Schmid KM, Preisack MB, Voelker W, Sujatta M, Karsch KR. First clinical experience with low molecular weight heparin LU 47311 (reviparin) for prevention of restenosis after percutaneous transluminal coronary angioplasty. Sem Thromb Hemost 1993; 19: 155-9.
7. [7] Serruys PW, De Jaegere P, Kiemeneij F, Macaya C, Rutsch W. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331: 489-98.
8. [8] Cowley MJ, Dorros G, Kelsey SF, Van Raden M, Detre KM. Acute coronary artery events associated with percutaneous transluminal coronary angioplasty. Am J Cardiol 1984; 53: 12C-16C.
9. [9] Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
10. [10] Jeske W, Lojewski B, Walenga JM, Hoppenstaeadt D, Ahsan A, Fareed J. Biochemical and pharmacologic profile of low molecular weight heparin (LU 47311, Clivarin). Sem Thrombosis Hemostasis 1993; 19: 229-40.
11. [11] Ueda M, Becker AE, Fujimoto T, Tsukada T. The early phenomena of restenosis following percutaneous transluminal coronary angioplasty. Eur Heart J 1991; 12: 937-45.
12. [12] Preisack MB, Athanasiadis A, Voelker , Baumbach A, Karsch KR. Acute closure during coronary excimer laser angioplasty and conventional balloon dilatation: a comparison of management, outcome and prediction. Eur Heart J 1993; 14: 195-204.
13. [13] Serruys PW, Hermann JP, Simon R et al. The Helvetica Investigators. A comparison of hirudin with Heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995; 333: 757-63.
14. [14] The EPIC Investigator. Use of a monoclonal antibody directed against the platelet glycoprotein Ilb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.
15. [15] Faxon DP. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR study, a multicenter, double-blind, placebo-controlled trial of Cilazapril. J Am Coll Cardiol 1995; 2: 362-9.
16. [16] Detre K, Holubkov R, Kelsey S et al. co-investigators of the NHLBI PTCA Registry. One-year follow-up results of the 1985-1986 National Heart, Lung, and Blood Institute's Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1989; 80: 421-8.
17. [17] Hirsh J. Heparin. N Engl J Med 1991; 324: 1565-74.
18. [18] Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 1: Heparin. Circulation 1994; 89: 1449-68.